Trial Profile

A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Dec 2021 Data was used from trials (PAZOGIST & GRID) to assess cost-effectiveness of pazopanib versus regorafenib as a third-line treatment for metastatic or unresectable gastrointestinal stromal tumors in Chinapresented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
05 Apr 2016 Primary endpoint has been met. (Progression-free survival), as per article published in the Lancet Oncology.
05 Apr 2016 Results published in the Lancet Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com